Islandia - Islandia - LYFJASTOFNUN (Icelandic Medicines Agency)

stada arzneimittel ag - carvedilolum inn - tafla - 3,125 mg

Islandia - Islandia - LYFJASTOFNUN (Icelandic Medicines Agency)

stada arzneimittel ag - carvedilolum inn - tafla - 6,25 mg

Islandia - Islandia - LYFJASTOFNUN (Icelandic Medicines Agency)

stada arzneimittel ag - carvedilolum inn - tafla - 12,5 mg

Islandia - Islandia - LYFJASTOFNUN (Icelandic Medicines Agency)

stada arzneimittel ag - carvedilolum inn - tafla - 25 mg

Islandia - Islandia - LYFJASTOFNUN (Icelandic Medicines Agency)

stada arzneimittel ag - clemastinum fúmarat - tafla - 1 mg

Uni Eropa - Islandia - EMA (European Medicines Agency)

bayer ag - rivaroxaban - arthroplasty, replacement; venous thromboembolism - blóðþurrðandi lyf - mælt, sam-gefið með asetýlsalisýlsýru (asa) einn eða með asa, plús eða eða tíclópidín, er ætlað til að fyrirbyggja atherothrombotic atburðum í fullorðinn sjúklinga eftir bráð kransæðastíflu (haft) með hækkun hjarta biomarkers. xarelto, co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events. til að koma í veg fyrir segareki í bláæðum (vte) hjá fullorðnum sjúklingum sem gangast undir valhimnubólgu eða meðhöndlun á hné. meðferð djúpt æð blóðtappa (hjá sjúklingum sem fengu) og í lungum stíflu (pe), og koma í veg fyrir endurteknum hjá sjúklingum sem fengu pe í fullorðnir. adultsprevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.

Uni Eropa - Islandia - EMA (European Medicines Agency)

bayer ag - vericiguat - hjartabilun - hjarta meðferð - treatment of symptomatic chronic heart failure.

Uni Eropa - Islandia - EMA (European Medicines Agency)

takeda pharmaceuticals international ag ireland branch - maribavir - cytomegalovirus sýkingar - veirueyðandi lyf til almennrar notkunar - livtencity is indicated for the treatment of cytomegalovirus (cmv) infection and/or disease that are refractory (with or without resistance) to one or more prior therapies, including ganciclovir, valganciclovir, cidofovir or foscarnet in adult patients who have undergone a haematopoietic stem cell transplant (hsct) or solid organ transplant (sot). Íhuga ætti að opinbera leiðsögn á réttri notkun af veirum.

Islandia - Islandia - LYFJASTOFNUN (Icelandic Medicines Agency)

stada arzneimittel ag - lacosamidum inn - filmuhúðuð tafla - 100 mg

Islandia - Islandia - LYFJASTOFNUN (Icelandic Medicines Agency)

stada arzneimittel ag - lacosamidum inn - filmuhúðuð tafla - 150 mg